QNCX
Quince Therapeutics, Inc. · Healthcare
0.09
11.62%(-0.01)
Prev. Close0.11
22.17%(+0.02)
Pre-marketLast Updated: — ET
52W L: $0.0852W H: $4.55
$0.10
CHG-0.00 (-0.51%)
H$0.13
L$0.07
VOL430M
QNCX (1h)
Quince Therapeutics, Inc. · Healthcare
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $QNCX #biotech--Quince Therapeutics, Inc. (Nasdaq: QNCX) today announced the successful settlement of the company's outstanding obligations under its loan from the European Investment Bank (EIB) for a payment of $5.5 million. This marks a material milestone for Quince as the completion of the settlement resolves critical debt obligations and allows the company to advance its restructuring and evaluation of strategic alternatives aimed at maximizing shareholder valu.
Shares of Quince Therapeutics, Inc. (NASDAQ: QNCX - Get Free Report) have earned a consensus recommendation of "Reduce" from the seven analysts that are presently covering the company, Marketbeat.com reports. Two analysts have rated the stock with a sell rating and five have given a hold rating to the company. The average twelve-month target price among
Shares of Quince Therapeutics, Inc. (NASDAQ: QNCX - Get Free Report) have received an average rating of "Reduce" from the nine brokerages that are currently covering the stock, MarketBeat Ratings reports. Two equities research analysts have rated the stock with a sell recommendation, six have given a hold recommendation and one has issued a buy recommendation
Quince Therapeutics shares surged 53% after hours Thursday following the engagement of LifeSci Capital as financial advisor amid restructuring and strategic plans.
Quince Therapeutics Inc (NASDAQ: QNCX) stock is trading sharply lower Thursday after the biotech company followed up Wednesday's rally with a Form 8-K that underscores how precarious its situation is. Here's what investors need to know amid this week's volatility.
Quince Therapeutics, Inc. (NASDAQ: QNCX - Get Free Report) was the recipient of unusually large options trading on Wednesday. Stock investors acquired 28,800 call options on the company. This represents an increase of 1,366% compared to the typical volume of 1,964 call options. Quince Therapeutics Stock Performance Shares of NASDAQ: QNCX opened at $0.61 on Thursday. Quince
Thye Dirk
director, officer: CEO and CMO
1,000,000 SH @ $3.08
2026-01-23
Ryan Charles S.
officer: President
200,000 SH @ $3.08
2026-01-23
Hannah Brendan
officer: CBO, COO & CCO
365,000 SH @ $3.08
2026-01-23
Senner Christopher J.
director
21,810 SH @ $3.00
2026-01-02
McLoughlin Margaret
director
19,547 SH @ $3.00
2026-01-02
Lamond David
director
29,423 SH @ $3.00
2026-01-02
Bray June
director
18,724 SH @ $3.00
2026-01-02
Benatti Luca
director
50,000 SH @ $3.47
2025-12-26